Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective study of ustekinumab dried blood spot concentrations in Crohn's disease
2019-002038-35Phase 4Completed
- Sponsor
- UZ Leuven
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ustekinumab in Crohn's disease, sponsored by UZ Leuven. Primary endpoint: Primary: Difference in ustekinumab concentrations by endoscopic response. Started Jun 2019; status: completed.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2019-002038-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002038-35.